Lynn Pieper, CFA, Managing Director

Lynn Pieper has worked on Wall Street covering the health care industry for fourteen years. She was most recently a Managing Director and portfolio manager at Aphelion Capital which is a fund focused on both public and private investments in the Medical Technology sector. Prior to founding Aphelion, Lynn was a partner and sellside analyst at Thomas Weisel Partners LLC where she built the Medical Device Equity Research product as part of the health care team in 2001. 

While at Thomas Weisel Partners, Lynn established the medical device platform as one of the preeminent franchises on Wall Street, focusing on deep industry research and high quality emerging growth opportunities within medical technology. Thomas Weisel Partners has been part of the underwriting team for several medical device IPOs during Lynn’s tenure at the firm, including TheraSense, Animas, NuVsive, ev3, AtriCure and Fox Hollow Technologies. Lynn has authored industry reports on several subsectors including cardiology, diabetes, orthopedics, spinal surgery, and pain management. 

Lynn joined Thomas Weisel Partners from Adams, Harkness & Hill, where she was the Senior Research analyst covering the medical device industry. Before joining Adams Harkness, Lynn provided fixed income research as part of Andrew Carter & Co.

Lynn holds the CFA designation and holds a Masters degree in Finance from Boston College Carroll School of Management. She graduated from University of Vermont with a degree in Environmental Science and Mathematics. Lynn is a frequent panel participant at industry tradeshows and is a member of the Board of Directors for the Juvenile Diabetes Research Foundation in the Bay area.